The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | Ivosidenib plus azacitidine for mIDH1 newly diagnosed AML
Paresh Vyas, MRCP, FRCP, FRCPath, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, discusses the ongoing Phase 1b trial (NCT02677922) investigating clonal evolution and resistance in patients with mutant isocitrate dehydrogenase 1 (mIDH1) newly diagnosed acute myeloid leukemia (AML) treated with ivosidenib plus azacitidine. The study found that ivosidenib plus azacitidine treatment led to deep and durable molecular remissions. Additionally, Dr Vyas discusses the results of a Phase 1b trial (NCT03248479) of the anti-CD47 antibody magrolimab combined with azacitidine in AML. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Paresh Vyas, MRCP, FRCP, FRCPath, has been on advisory boards for Gilead and Agios.
